Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Quetiapine in Huntington's disease: a first case report.

Literature DB >> 12420714

Quetiapine in Huntington's disease: a first case report.

Raphael M Bonelli, Gerald Niederwieser.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2002 PMID： 12420714 DOI： 10.1007/s00415-002-0741-1

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

× No keyword cloud information.

12 in total

1. Olanzapine and Huntington's disease.

Authors: G Bogelman; S Hirschmann; I Modai
Journal: J Clin Psychopharmacol Date: 2001-04 Impact factor: 3.153

2. The use of olanzapine for movement disorder in Huntington's disease: a first case report.

Authors: H C Dipple
Journal: J Neurol Neurosurg Psychiatry Date: 1999-07 Impact factor: 10.154

3. Risperidone in treatment of choreoathetosis of Huntington's disease.

Authors: M A Parsa; E Szigethy; J M Voci; H Y Meltzer
Journal: J Clin Psychopharmacol Date: 1997-04 Impact factor: 3.153

4. Improvement of Huntington's disease with olanzapine and valproate.

Authors: V E Grove; J Quintanilla; G T DeVaney
Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245

5. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

Authors: J P van Vugt; S Siesling; M Vergeer; E A van der Velde; R A Roos
Journal: J Neurol Neurosurg Psychiatry Date: 1997-07 Impact factor: 10.154

6. Neuroleptically induced dystonia in Huntington's disease: a case report.

Authors: K Schott; S Ried; I Stevens; J Dichgans
Journal: Eur Neurol Date: 1989 Impact factor: 1.710

7. Use of risperidone in psychosis associated with Huntington's disease.

Authors: S Madhusoodanan; R Brenner
Journal: Am J Geriatr Psychiatry Date: 1998 Impact factor: 4.105

8. Effectiveness of risperidone in Huntington chorea patients.

Authors: C Dallocchio; C Buffa; C Tinelli; P Mazzarello
Journal: J Clin Psychopharmacol Date: 1999-02 Impact factor: 3.153

9. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.

Authors: C M Stephenson; V Bigliani; H M Jones; R S Mulligan; P D Acton; D Visvikis; P J Ell; R W Kerwin; L S Pilowsky
Journal: Br J Psychiatry Date: 2000-11 Impact factor: 9.319

10. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.

Authors: E C Etchebehere; M C Lima; W Passos; J A Maciel Júnior; A O Santos; C D Ramos; E E Camargo
Journal: Arq Neuropsiquiatr Date: 1999-09 Impact factor: 1.420

11 in total

1. Treatment of huntington disease.

Authors: Aleksandar Videnovic
Journal: Curr Treat Options Neurol Date: 2013-08 Impact factor: 3.598

Review 2. Huntington's Disease-Update on Treatments.

Authors: Kara J Wyant; Andrew J Ridder; Praveen Dayalu
Journal: Curr Neurol Neurosci Rep Date: 2017-04 Impact factor: 5.081

Review 3. Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors: Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal: Histol Histopathol Date: 2008-02 Impact factor: 2.303

Review 4. Treatment of Huntington's disease.

Authors: Samuel Frank
Journal: Neurotherapeutics Date: 2014-01 Impact factor: 7.620